Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL

BACKGROUND: Blinatumomab has shown a remission rate of 69% in an exploratory single-arm, phase II dose-escalation study in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL). We evaluated changes in laboratory parameters and immunopharmacodynamic markers in patien...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Exp Hematol Oncol
Autors principals: Nägele, Virginie, Kratzer, Andrea, Zugmaier, Gerhard, Holland, Chris, Hijazi, Youssef, Topp, Max S., Gökbuget, Nicola, Baeuerle, Patrick A., Kufer, Peter, Wolf, Andreas, Klinger, Matthias
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2017
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5437652/
https://ncbi.nlm.nih.gov/pubmed/28533941
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-017-0074-5
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars